Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [<i>Grupo de Estudio de Linfoproliferativos de Latino América</i> (GELL)]

Villela, Luís; Torre-Viera, María; Idrobo-Quintero, Henry; Beltrán, Brady E

doi:10.1080/16078454.2022.2141960

Cited by 3 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell lymphoma (TCL) is highly heterogeneous and aggressive hematological malignancy, and TCL patients tend to have worse clinical outcomes than those with B-cell lymphoma. [1][2][3][4][5][6] Currently, based on the International Prognostic Index (IPI), the risk stratification has made great progress in TCL patients, which provide important reference for making precise clinical therapy strategy, thereby improving the clinical outcomes of patients. [7][8][9] However, IPI still cannot accurately stratify all TCL patients.…”

Section: Introductionmentioning

confidence: 99%

T‐cell lymphoma patient harboring BCL11B mutations had favorable overall survival

Chen,

Huang,

Liu

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

BackgroundMolecular genetics serve a critical role in constructing risk stratification for hematological malignancies, but T‐cell lymphoma (TCL) still lacks molecular genetic information for supplement risk stratification in predicting the prognosis of TCL patients. In the present study, we characterized the mutation patterns of B‐cell leukemia/lymphoma 11B gene (BCL11B) and its prognostic importance in TCL patients.MethodsBCL11B mutations were characterized based on the data from two datasets, one is from our clinical center (GDPH dataset, n = 79) and the other is from COSMIC dataset (n = 154).ResultsThe overall mutation rate of BCL11B was 6.4% (15/233) in TCL, and there were no hotspot mutation sites in TCL. Among these mutations, the missense and splice site mutation were significantly prominent. Moreover, TCL patients harboring BCL11B mutations had a favorable overall survival (OS) in our center (GDPH dataset) (adjusted hazard ratio [HR] = .001, p = 0.109), although there were not yet significantly statistical at this point. In addition, TCL patients harboring BCL11B mutation had a longer 5‐year restricted mean survival time (RMST) than those without a BCL11B mutation (60 vs. 32 months). Notably, BCL11B mutations were not associated with TCL entities having better prognosis.ConclusionsBCL11B mutations were associated with favorable clinical outcome for TCL patients; it might be considered as a novel biomarker for TCL prognostic stratification.

show abstract

Section: Introductionmentioning

confidence: 99%

T‐cell lymphoma patient harboring BCL11B mutations had favorable overall survival

Chen,

Huang,

Liu

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy

Cabrera,

Peña,

Vega

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundFollicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma (NHL) in the United States and Europe. However, data on FL from Latin America are scant.AimsThis study aims at better understand the clinical features, treatment patterns and outcomes of patients with FL in Chile. Of special interest was to evaluate POD24 as an adverse marker.Methods and ResultsWe collected retrospective data from 722 patients 15 years or older diagnosed with FL and treated in 17 cancer centers in Chile between 2000 and 2019. Time to first treatment (TTFT), progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional‐hazard regression models were fitted to investigate prognostic factor. The median age at diagnosis was 62 with a female predominance (63%); 73% of patients had advance stage disease and 68% had bone marrow involvement; 63% had intermediate or high FLIPI scores. The 1‐year TTFT rate was 96%, and 30% of patients received chemoimmunotherapy. Adding rituximab to chemotherapy was associated with a higher complete response (69% vs. 60%; p < 0.001) and superior median OS (16 vs. 8 years; p < 0.001). Patients who experience POD24 had an inferior median OS (2.4 vs. 15 years).ConclusionOur study shows a female predominance in patients with FL in Chile and confirms superior response and survival outcomes with adding rituximab to chemotherapy. Our study also confirms a poor OS in patients who experience POD24.

show abstract

Oral manifestations of peripheral T cell lymphoma, not otherwise specified: case series and review of the current literature

de Oliveira,

de Cáceres,

Fernandes-Rodrigues

et al. 2024

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)]

Cited by 3 publications

References 25 publications

T‐cell lymphoma patient harboring BCL11B mutations had favorable overall survival

T‐cell lymphoma patient harboring BCL11B mutations had favorable overall survival

Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy

Oral manifestations of peripheral T cell lymphoma, not otherwise specified: case series and review of the current literature

Contact Info

Product

Resources

About